The results of the double-blind, placebo-controlled study on the prevention and relief of upper respiratory infections will be published tomorrow. Edmonton, Alberta's Medical Officer of Health and a professor at the University of Alberta.conducted the clinical trial.
The number of upper respiratory infections in each subject was significantly reduced by 25% in the COLD-fX group during the 4 month treatment period. Also, recurrent infections were reduced by 56% (10.0% in the COLD-fX group v. 22.8% in the placebo group, an absolute difference of 12.8%). COLD-fX treatment also had a significant effect in reducing the total symptom score and the duration of infections. The incidence of adverse events was low and the prevalence was found to be similar between the two groups.
The study involved 323 adults from the general population (18-65 years of age) with a history of at least two upper respiratory infections in the previous year. Participants were given either COLD-fX or a placebo for four months during the winter of 2003/04. Subjects graded the severity and duration of their respiratory-related symptoms on a 4-point scale. All analysis was performed by a biostatistician under blinded conditions.
The authors of the study, Dr. Gerry Predy of the Capital Health in Edmonton and Dr. Tapan Basu of the University of Alberta, concluded that the COLD-fX treatment appeared to be an attractive natural prophylactic treatment for upper respiratory infections. Regular intake of COLD-fX was shown in the clinical trial to be effective not only for the prevention of upper respiratory infections, but also for relief of symptoms if an infection did occur. The results wer
Contact: Ryan Smith
University of Alberta